Presenilin-1 but not amyloid precursor protein mutations present in mouse models of Alzheimer’s disease attenuate the response of cultured cells to γ-secretase modulators regardless of their potency and structure
Authors:
- 13 December 2010
- journal article
- research article
- Published by Wiley in Journal of Neurochemistry
- Vol. 116 (3) , 385-395
Abstract
γ-Secretase modulators (GSMs) inhibit the generation of amyloidogenic Aβ42 peptides and are promising agents for treatment or prevention of Alzheimer's disease (AD). Recently, a second generation of GSMs with favorable pharmacological properties has emerged, but preclinical studies to assess their efficacy in vivo are lacking. Such studies rely on transgenic mouse models that express amyloid precursor protein (APP) and presenilin (PSEN) mutations associated with early-onset familial AD. Previously, we have shown that certain PSEN1 mutations attenuated the response of cultured cells to GSMs and potentially confound in vivo studies in AD mouse models. However, different combinations of familial AD mutations might have synergistic or opposing effects, and we have now systematically determined the response of APP and PSEN1 mutations present in current AD models. Using a potent acidic GSM, we found that APP mutations, either single mutations or in combination, did not affect the potency of GSMs. In contrast, all PSEN1 mutations that have been used to accelerate pathological changes in AD models strongly attenuated the Aβ42-lowering activity of GSMs with two exceptions (M146L, A246E). Similar results were obtained with potent non-acidic GSMs indicating that the attenuating effect of PSEN1 mutations cannot simply be overcome by increased potency or structural changes. Notably, two non-acidic compounds fully compensated the attenuating effect of the PSEN1-G384A mutation. Taken together, our findings indicate that most AD models with rapid pathology and advanced phenotypes are unsuitable for preclinical GSM studies. However, we also provide evidence that additional compound screens could discover GSMs that are able to break the attenuating effects of PSEN mutations.Keywords
This publication has 50 references indexed in Scilit:
- Modulation of γ-Secretase Reduces β-Amyloid Deposition in a Transgenic Mouse Model of Alzheimer's DiseaseNeuron, 2010
- Amyloid beta 42 peptide (Aβ42)-lowering compounds directly bind to Aβ and interfere with amyloid precursor protein (APP) transmembrane dimerizationProceedings of the National Academy of Sciences, 2010
- β-Amyloid Precursor Protein Mutants Respond to γ-Secretase ModulatorsJournal of Biological Chemistry, 2010
- Probing the Biology of Alzheimer's Disease in MiceNeuron, 2010
- The secretases: enzymes with therapeutic potential in Alzheimer diseaseNature Reviews Neurology, 2010
- CHF5074, a novel γ‐secretase modulator, attenuates brain β‐amyloid pathology and learning deficit in a mouse model of Alzheimer's diseaseBritish Journal of Pharmacology, 2009
- Substrate-targeting γ-secretase modulatorsNature, 2008
- Alzheimer disease models and human neuropathology: similarities and differencesActa Neuropathologica, 2007
- BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic miceNeurobiology of Disease, 2007
- Aβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathologyEMBO Reports, 2006